Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease The successful study outcome could significantly boost the drug’s sales if it’s cleared by regulators

https://www.statnews.com/2026/05/05/cytokinetics-myqorzo-non-obstructive-hypertrophic-cardiomyopathy-trial/ By Adam FeuersteinMay 5, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.